InnovAge appoints Dr. Paul Taheri as Chief Medical Officer, enhancing leadership with over 30 years in healthcare.
Quiver AI Summary
InnovAge Holding Corp. has appointed Dr. Paul Taheri as its new Chief Medical Officer, effective November 3, 2025. Dr. Taheri, who is a board-certified trauma surgeon with over 30 years of healthcare leadership experience, has held various significant positions, including Clinical Quality Advisor at Welsh, Carson, Anderson & Stowe and CEO at Yale School of Medicine. His appointment is seen as a strategic enhancement for InnovAge, which focuses on providing comprehensive healthcare programs to frail seniors, particularly those who are dual-eligible for Medicare and Medicaid. The company's mission is to help older adults age independently at home while improving care quality and reducing unnecessary high-cost care. InnovAge currently serves approximately 7,740 participants across 20 centers in six states.
Potential Positives
- Appointment of Dr. Paul Taheri as Chief Medical Officer adds significant leadership experience and clinical expertise to InnovAge, which can enhance the quality of care provided to participants.
- Dr. Taheri's extensive background in healthcare management, including previous leadership roles in prominent medical institutions, positions InnovAge to strengthen its operational and clinical strategies.
- The press release reinforces InnovAge's commitment to improving care for frail seniors, aligning with its mission to enable older adults to age independently, which could improve brand reputation and attract more participants.
Potential Negatives
- Appointment of a new Chief Medical Officer could indicate previous leadership gaps or instability within the company, raising concerns about internal operations.
- The press release lacks specific details on how Dr. Taheri's leadership will strategically improve the company's performance or address current challenges in the organization.
- The focus on a new appointment without addressing any current issues may come off as an attempt to distract from potential corporate challenges or controversies.
FAQ
Who has been appointed as the Chief Medical Officer of InnovAge?
Dr. Paul Taheri has been appointed as the Chief Medical Officer of InnovAge, effective November 3, 2025.
What experience does Dr. Paul Taheri bring to InnovAge?
Dr. Taheri brings over 30 years of healthcare leadership experience, having held various roles including CEO at the Yale School of Medicine.
What is the mission of InnovAge?
InnovAge's mission is to enable older adults to age independently in their homes while improving the quality of care they receive.
How many participants does InnovAge serve?
As of June 30, 2025, InnovAge serves approximately 7,740 participants across 20 centers in six states.
What healthcare model does InnovAge utilize?
InnovAge utilizes the Program of All-inclusive Care for the Elderly (PACE) model to manage care for dual-eligible seniors effectively.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INNV Insider Trading Activity
$INNV insiders have traded $INNV stock on the open market 11 times in the past 6 months. Of those trades, 11 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $INNV stock by insiders over the last 6 months:
- RICHARD C ZORETIC has made 8 purchases buying 48,653 shares for an estimated $197,932 and 0 sales.
- MICHAEL ANTHONY SCARBROUGH (President and COO) has made 3 purchases buying 33,000 shares for an estimated $122,890 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$INNV Hedge Fund Activity
We have seen 30 institutional investors add shares of $INNV stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAMBIAR INVESTORS LLC removed 229,987 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,186,732
- KENT LAKE PR LLC added 197,036 shares (+13.1%) to their portfolio in Q2 2025, for an estimated $727,062
- WINNOW WEALTH LLC added 100,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $369,000
- VANGUARD GROUP INC added 84,619 shares (+8.2%) to their portfolio in Q2 2025, for an estimated $312,244
- WELCH CAPITAL PARTNERS LLC/NY added 82,868 shares (+22.6%) to their portfolio in Q2 2025, for an estimated $305,782
- GOLDMAN SACHS GROUP INC removed 73,805 shares (-77.8%) from their portfolio in Q2 2025, for an estimated $272,340
- BNP PARIBAS FINANCIAL MARKETS removed 48,241 shares (-95.4%) from their portfolio in Q2 2025, for an estimated $178,009
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$INNV Analyst Ratings
Wall Street analysts have issued reports on $INNV in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Underweight" rating on 09/18/2025
To track analyst ratings and price targets for $INNV, check out Quiver Quantitative's $INNV forecast page.
Full Release
DENVER, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), appoints Paul Taheri, MD, MBA as its Chief Medical Officer, effective November 3, 2025.
Dr. Paul Taheri, a board-certified trauma surgeon, brings more than 30 years of healthcare leadership to InnovAge. He has served as a Clinical Quality Advisor to Welsh, Carson, Anderson & Stowe, a role he has held since 2019. Dr. Taheri previously served as CEO and Deputy Dean for Clinical Affairs at the Yale School of Medicine. His earlier leadership roles include President and CEO of the University of Vermont Medical Group, Senior Associate Dean for Clinical Affairs, and professor of surgery. He also held key positions at the University of Michigan in Ann Arbor, where he earned his MBA from the Ross School of Business. Dr. Taheri received his medical degree from New York University and completed his surgical residency at Tulane University.
“Paul brings a rare combination of clinical excellence, operational discipline, and strategic leadership to InnovAge,” said Patrick Blair, CEO. “With more than 3 decades of healthcare experience and his knowledge as a provider, we welcome him to InnovAge and are excited about the experience and stead leadership we expect him to bring to our clinical teams and the participants we serve every day.”
About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of June 30, 2025, InnovAge served approximately 7,740 participants across 20 centers in six states.
https://www.innovage.com/
.
Investor Contact:
Ryan Kubota
[email protected]
Media Contact:
Lara Hazenfield
[email protected]
This press release was published by a CLEAR® Verified individual.
